Mega-mergers may cut costs, but they won’t fix pharma’s innovation gap. Breakthroughs come through biotech partnerships, ...
A potential AstraZeneca (AZN) acquisition of Bristol-Myers Squibb (BMY) is unlikely to happen now after a report that the pharma giants have held deal talks, according to an RBC analyst. "Achieving ...
Concerns mounted after the failure of Wainua, an approved treatment for rare neurological disorder ATTR-CM, in a Phase III ...
Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the ...
The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent to management's credibility, according to Jefferies. The shares fell 9% and ...
By Pushkala Aripaka and Maggie Fick July 27 (Reuters) - AstraZeneca stood by its annual and long-term forecasts on Monday, ...
Tech Times on MSN
AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer
AstraZeneca Bristol Myers Squibb merger talks could create a $400 billion pharmaceutical giant — the largest in history — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results